| Trial ID # | NCT03699449 |
| Phase | II |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Olaparib |
| Alternate Drug Names | AZD2281, Lynparza |
| Drugs in Trial | Durvalumab, Olaparib |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | Arm B: 14 HRRm Pt-R ovarian cancer, median 4 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, evaluated per RECIST |
| Biomarkers | HRRm panel: ATM, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCL, PALB2, PPP2R2A, RAD51 B/C/D, RAD54L |
| Efficacy | ORR: 35.7% (5PR, n=14) - all responders BRCA1/2 MUT |
| Conclusion | Olaparib+durvalumab shows promising activity in BRCA MUT patients |
| Reference | Lee J-Y et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION). J Clin Oncol (2021) 39 (suppl 15; abstr 5520) Lee J-Y et al. Poster Lee J-Y et al. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J Gynecol Oncol (2022) 33(4):e45 |